Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyQualChoice Exdensur (depemokimab‑ulaa) Coverage Up…
    Ask Trek AI about this page
    ModifiedQualChoicePolicy HIM.PA.179

    Clinical Policy: Depemokimab-ulaa (Exdensur)

    Customize your policy alerts

    Sign up for QualChoice Policy HIM.PA.179 alerts

    Get alerted when Policy HIM.PA.179 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and coverage criteria for Exdensur (depemokimab-ulaa) as add-on maintenance treatment of severe eosinophilic asthma for eligible members; applies to QualChoice HIM line of business.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Depemokimab-ulaa (Exdensur)
    Policy CodePolicy HIM.PA.179
    Change TypeCoding update (added J2361removed unlisted codes)
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionObtain prior authorization using HCPCS code J2361 and submit supporting clinical documentation including recent eosinophil count and exacerbation history.
    SourceLink
    POLICY UPDATE CHANGES

    Added HCPCS code J2361 and removed miscellaneous/unlisted codes (J3590 and others).

    Added HCPCS code J2361.

    100 mgdose per administration (maximum)
    every 6 monthsdosing interval
    ≥150 cells/mcLrequired blood eosinophil count for initiation
    ≥2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    exacerbations in prior 12 months required for initial approval
    12 monthsapproval duration
    J2361HCPCS code added

    Coverage Criteria for Depemokimab-ulaa (Exdensur)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Severe Asthma Criteria: 1. Diagnosis of asthma; 2. Member has an absolute blood eosinophil count ≥ 150 cells/mcL within the past 3 months; 3. Prescribed by or in consultation with an allergist, immunologist, or pulmonologist; 4. Age ≥ 12 years; 5. Member has experienced ≥ 2 exacerbations within the last 12 months requiring either (a) systemic/oral corticosteroid treatment (or increase in dose if already on oral corticosteroid) OR (b) urgent care/ER visit or hospital admission despite adherent use of controller therapy (medium- to high-dose inhaled corticosteroid [ICS] plus either a long-acting beta-2 agonist [LABA] or leukotriene modifier [LTRA] if LABA contraindicated/intolerant); 6. Failure of Dupixent and Fasenra each used for ≥ 4 consecutive months at up to maximally indicated doses unless clinically significant adverse effects or contraindications apply (note: Illinois HIM requests are exempt from step therapy per IL HB 5395 as of 1/1/2026); 7. Exdensur is prescribed concurrently with an ICS plus either a LABA or LTRA; 8. Exdensur is not prescribed concurrently with Cinqair, Fasenra, Nucala, Dupixent, Xolair, or Tezspire; 9. Dose does not exceed 100 mg every 6 months.

    Follow step therapy exceptions for Illinois as noted in policy.

    Continuation Therapy

    Continued coverage when ALL of the following are met:

    Continued Severe Asthma Criteria: 1. Member currently receiving medication via Centene benefit or has previously met initial approval criteria OR member is currently receiving medication and is enrolled in a state/product with continuity of care regulations; 2. Demonstrated adherence to asthma controller therapy (an ICS plus either a LABA or LTRA) as evidenced by proportion of days covered (PDC) ≥ 0.8 in the last 6 months; 3. Member is responding positively to therapy (examples include but are not limited to: reduction in exacerbations or corticosteroid dose, improvement in FEV1 since baseline, reduction in rescue therapy); 4. Exdensur is not prescribed concurrently with Cinqair, Fasenra, Nucala, Dupixent, Xolair, or Tezspire; 5. If request is for a dose increase, the new dose does not exceed 100 mg every 6 months.

    Other/Label Changes

    Other indications (non-standard or recently changed labeling):

    Other Indications: 1. If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy (e.g., new indication, age expansion, or dosing change), refer to: a) HIM.PA.33 (no coverage criteria) for drugs on the formulary/PDL OR b) HIM.PA.103 (non-formulary policy) for drugs not on the formulary/PDL; 2. If the requested use (diagnosis, age, dosing regimen) is NOT listed under section III (Diagnoses/Indications for which coverage is NOT authorized) and criterion 1 does not apply, refer to the off-label use policy HIM.PA.154 for the relevant line of business.

    Exdensur is not indicated for the treatment of acute bronchospasm or status asthmaticus. Requests for coverage to treat these acute conditions are not authorized under this policy.

    When there is a conflict between this clinical policy and state Medicaid coverage provisions for Medicaid members, the state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for any differing coverage rules.

    Uses of Exdensur that are not FDA‑approved and are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety consistent with the Health Plan’s off‑label use policy (HIM.PA.154) or applicable evidence‑of‑coverage documents.

    Coding and Billing

    Relevant HCPCS CodesHCPCSCovered
    J2361Injection, depemokimab-ulaa, 1 mg
    Covered HCPCS Codes / Coding updateHCPCSCovered
    J2361Injection, depemokimab-ulaa, 1 mg
    Removed/previous codesHCPCSNot Covered
    J3590Unclassified biologics (removed from policy)
    Absolute blood eosinophil count
    ThresholdAbsolute blood eosinophil count ≥ 150 cells/mcL
    TimingMeasured within the past 3 months
    UseRequired for initial approval for severe eosinophilic asthma
    Proportion of days covered (PDC)
    ThresholdProportion of days covered (PDC) ≥ 0.8
    TimeframeCalculated over the last 6 months (≥144 days of controller therapy out of 180 days)

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required; use HCPCS J2361

    Prior authorization is required for Exdensur (depemokimab-ulaa); include supporting clinical documentation with the request and bill using HCPCS code J2361 (Injection, depemokimab-ulaa, 1 mg).

    • Attach office chart notes, lab results (e.g., eosinophil count), and documentation of exacerbation history when submitting the PA request.
    Prior Authorization

    PA applies; bill with J2361

    Prior authorization requirements for depemokimab-ulaa apply per the Health Plan; claims should be submitted using HCPCS code J2361 for depemokimab-ulaa, 1 mg.

    • Verify current Health Plan prior authorization processes and include J2361 on claim submissions.

    Definitions and Reference Metrics

    PDC — Proportion of days covered
    DefinitionProportion of days covered (PDC) = sum of days covered in a timeframe ÷ number of days in the timeframe
    Continuation requirementPDC ≥ 0.8 in the last 6 months required for continued coverage
    InterpretationPDC ≥ 0.8 corresponds to ~144 days covered out of the last 180 days (≈5 of 6 months)
    Severe eosinophilic asthma — definitions and thresholds
    Eosinophil thresholdBlood eosinophils ≥150 cells/mcL
    Exacerbation requirement≥2 exacerbations in the prior 12 months despite controller therapy
    Background therapy

    Background

    Depemokimab‑ulaa (Exdensur) is an interleukin‑5 antagonist monoclonal antibody approved as an add‑on maintenance treatment for severe eosinophilic asthma in appropriate patients. It is intended for use as part of controller therapy and is not for acute rescue treatment.

    Revision History and Policy Changes

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Depemokimab-ulaa (Exdensur)
    Policy CodePolicy HIM.PA.179
    Change TypeCoding update (added J2361removed unlisted codes)
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionObtain prior authorization using HCPCS code J2361 and submit supporting clinical documentation including recent eosinophil count and exacerbation history.
    SourceLink
    On This Page
    Coverage Criteria for Depemokimab-ulaa (Exdensur)Coding and BillingProvider Actions, Prior Authorization & DocumentationDefinitions and Reference MetricsBackgroundRevision History and Policy Changes
    Purpose
    Evidence of adherence to asthma controller therapy for continuation of Exdensur
    Step Therapy

    Step therapy: failure of Dupixent and Fasenra required

    Step therapy requires documented failure of both Dupixent and Fasenra, each used for ≥ 4 consecutive months at up to maximally indicated doses, unless clinically significant adverse effects or contraindications are documented.

    • Illinois HIM requests are exempt from this step therapy requirement per IL HB 5395 effective 1/1/2026.
    Note

    Ensure complete documentation and coding on submission

    Ensure the request includes all required supporting documentation and coding information; incomplete submissions may delay review.

    • Provide office notes, recent absolute blood eosinophil count (within 3 months), exacerbation records, controller therapy adherence, and prior biologic trial details.
    Documentation Required

    Submit clinical documentation supporting approval criteria

    Provider must submit documentation (office notes, labs, or other clinical information) showing the member meets all approval criteria, including recent eosinophil count and exacerbation history.

    • Include absolute blood eosinophil count within past 3 months and evidence of ≥2 exacerbations in prior 12 months when applicable.
    Documentation Required

    Documentation and coding guidance

    Providers should follow up-to-date professional coding guidance and supply supporting clinical documentation consistent with medical necessity and Health Plan coverage terms.

    • Reference current coding manuals and Health Plan coding guidance when selecting HCPCS codes for claims.
    Denial Risk

    Insufficient documentation may result in denial or delay

    Requests that do not include documentation proving the member meets all approval criteria (diagnosis, eosinophil count, prior exacerbations, concomitant controller therapy, prior biologic trials or exemptions, prescriber specialty, age) may be denied or delayed.

    • Missing recent eosinophil count, lack of exacerbation documentation, absent prior biologic trial records, or omission of prescriber specialty are common reasons for denial.
    Billing Rule

    Coding mismatch (e.g., use of J3590) may trigger denial

    Claims billed with codes removed from this policy (for example J3590) may be inconsistent with updated coding guidance and risk denial if not billed with the current HCPCS code J2361.

    • Do not use unlisted/removed codes such as J3590 for depemokimab-ulaa; submit J2361 instead.
    Criteria applied despite medium- to high-dose ICS plus at least one additional controller
    Product prescribing information (December 2025) — Exdensur
    DocumentExdensur Prescribing Information (December 2025)
    SourceGlaxoSmithKline LLC; December 2025 (accessible via exdensur.com)
    Use in policyReferenced in policy Appendix D as the product prescribing information supporting indications and dosing
    Global Initiative for Asthma (2025 updates)
    GuidanceGlobal Initiative for Asthma: Global strategy for asthma management and prevention (2025 update)
    Specific resourceGINA difficult-to-treat and severe asthma in adolescent and adult patients, v6.0, 2025
    Policy roleCited in Appendix D as a referenced guideline informing severe asthma management